Systemic Inflammation Reprograms Human Hepatic Phenotype and Suppresses ADME Gene Expression: Validation in a 3D Human Liver Spheroid System

DRUG METABOLISM AND DISPOSITION · Published 2026-08-01 · DOI 10.1016/j.dmd.2026.100384

Authors (6)

Inger Johansson, Allan Zhao, Lili Milani, Qiaolin Deng, Magnus Ingelman-Sundberg, Sander van Riet

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Johansson, I., Zhao, A., Milani, L., et al. (2026). Systemic Inflammation Reprograms Human Hepatic Phenotype and Suppresses ADME Gene Expression: Validation in a 3D Human Liver Spheroid System. DRUG METABOLISM AND DISPOSITION. https://doi.org/10.1016/j.dmd.2026.100384

Related articles

• Virtual special section: Gut microbiota in drug metabolism · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• A 3-step static mechanistic modeling approach to predicting transporter- and enzyme-mediated interaction signals of direct oral anticoagulants · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Investigation of biomarkers for azole antifungal-induced liver injury using primary human hepatocyte spheroids · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Physiologically based pharmacokinetic modeling of the unusual kinetics of ketoconazole due to nonlinear liver binding and metabolism in rats · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Role of CYP3A5 and CYP3A4 in the metabolism and toxicity of 10-hydroxyl mesaconitine, a new potential toxicity marker of Radix Aconiti Lateralis Preparata (Fuzi), in vitro and in vivo · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids—Application to recent real-world cases · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• A comprehensive investigation into the effect of bisphenol A on the expression of drug-metabolizing enzymes: Consequences for endogenous metabolites and xenobiotic pharmacokinetics · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Mechanistic Study on the Species Differences in Metabolism and Excretion Pathways of Ivarmacitinib (SHR0302) between Humans and Rats · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal